Influenza antibody, preparation method, preparation and pharmaceutical composition
By designing influenza antibodies with specific amino acid sequences and optimizing their binding epitope, the problems of poor broad spectrum and high production cost of existing antibodies are solved, and efficient neutralization and prevention effects on most influenza A viruses are achieved.
Patent Information
- Application Number
- CN202411053258.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-02
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The broad spectrum of existing influenza virus antibodies is poor, making it difficult to effectively neutralize most influenza A viruses. The emerging mutant strains may offset the effects of existing antibodies, and the antibody development technology is high and the production cycle is long.
Design an influenza antibody that includes a specific amino acid sequence, purified by inserting eukaryotic expression vectors and expressing in Expi-CHO cells, and replaced the antibody binding table by optimizing site screening and HA docking analysis. side chain amino acids at the site to improve binding activity and viral neutralization activity.
It has achieved efficient neutralization of most influenza A viruses, significantly improved binding activity and virus neutralization activity, provided better preventive effects, and reduced production costs and cycles.
Smart Images

Figure CN118909104A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of immune antibody technology, and in particular to an influenza antibody, a preparation method, a preparation and a pharmaceutical composition. Background Art
[0002] Influenza viruses have long been a threat to human health and have caused huge economic losses to human society. The World Health Organization monitors the prevalence and transmission patterns of influenza virus every year and recommends annual vaccination, which is the most effective prevention and control strategy. The continuous emergence of mutant strains and drug-resistant strains also poses a huge challenge to the development of effective vaccines. Therefore, finding new treatments remains urgent.
[0003] Broadly neutralizing antibodies are an effective strategy for preventing viral infection. Hemagglutinin (HA) on the surface of influenza virus is a key glycoprotein that mediates viral infection of host cells. Its stem region (HA2) is highly conserved and can induce broad cross-reactions. Broadly neutralizing antibodies targeting HA2 are expected to neutralize most influenza A viruses. Many monoclonal antibody drugs have entered the clinical trial stage, including CR6261, CR8020, MHAA4549A and MEDI8852, and the recognition sites of the above antibodies are located in the HA stem region.
[0004] There are many challenges in developing broad-spectrum neutralizing antibodies against influenza virus surface proteins. First, viral surface proteins are highly variable in different subtypes, especially antibodies targeting the receptor binding region (RBS) of the HA head. Such antibodies can generally detect hemagglutination inhibition activity in vitro, but their broad spectrum is poor, which greatly limits their clinical application as therapeutic antibodies. Secondly, the emergence of new influenza viruses with natural escape mutations may offset the effects of existing broad-spectrum neutralizing antibodies. At present, antibody development technology is mainly based on phage display and single B cell production technology, but the above technologies have long production cycles and high costs. Therefore, how to screen influenza neutralizing antibodies in large quantities through efficient and sensitive methods, or to explore how to optimize the neutralizing activity of existing antibodies through some method, will help the research and development of broad-spectrum neutralizing antibodies for influenza.
[0005] In summary, how to design an optimized influenza antibody, and then optimize the activity of influenza neutralizing antibodies, and prevent influenza virus infection, is a problem that needs to be solved urgently by technicians in this field. Summary of the invention
[0006] The technical solution of the present invention to solve the above technical problem is to provide an influenza antibody, wherein the influenza antibody comprises a light chain variable region, and the light chain variable region has an amino acid sequence shown in SEQ ID NO:1.
[0007] Furthermore, the influenza antibody is of the type of immunoglobulin molecule, complementary determining region fragment, nanobody, single-chain antibody, double-chain antibody, three-chain antibody or four-chain antibody.
[0008] In order to solve the above technical problems, the present invention also provides a method for preparing influenza antibodies, comprising the following steps:
[0009] The amino acid sequence of SEQ ID NO: 1 in the influenza antibody described above was inserted into the eukaryotic expression vector PVAX1, and then transfected into the supernatant of Expi-CHO cells for expression;
[0010] When the cell survival rate reaches 70%, the supernatant is taken out for purification by Protein A affinity chromatography to obtain the antibody.
[0011] Furthermore, the method for preparing influenza antibodies also includes:
[0012] The screening of optimized sites was carried out by analyzing the docking of antibodies and HA and screening the side chain amino acids located in the binding epitope.
[0013] In order to solve the above technical problems, the present invention also provides an influenza antibody preparation, which comprises the influenza antibody as described above.
[0014] In order to solve the above technical problems, the present invention also provides a pharmaceutical composition, comprising the influenza antibody and a carrier thereof as described above.
[0015] The influenza antibody of the present invention includes a light chain variable region, and the light chain variable region has an amino acid sequence as shown in SEQ ID NO: 1. The amino acid sequence of the influenza neutralizing antibody of the present invention involves a light chain variable region as shown in SEQ ID NO: 1, and an optimized antibody with better binding activity and virus neutralization activity is obtained by replacing the side chain amino acids in the antibody binding epitope, which has a better preventive effect than the unoptimized wild-type antibody. BRIEF DESCRIPTION OF THE DRAWINGS
[0016] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the structures shown in these drawings without paying creative work.
[0017] Figure 1 This is a schematic diagram of the antibody structure modeling of the present invention;
[0018] Figure 2 This is a diagram showing the expression and purification results of the influenza antibody (3W40I) of the present invention.
[0019] Figure 3 This is a diagram showing the binding ability analysis of the influenza antibody of the present invention.
[0020] Figure 4 The figure is a result diagram of the virus neutralization activity of the influenza antibody of the present invention.
[0021] Figure 5 This is a diagram showing the inhibition of virus invasion and release by the influenza antibody of the present invention. DETAILED DESCRIPTION
[0022] The present invention provides an influenza antibody, a preparation method, a preparation and a pharmaceutical composition, aiming to design an optimized influenza antibody, thereby optimizing the activity of influenza neutralizing antibodies and preventing influenza virus infection.
[0023] The influenza antibodies proposed by the present invention will be described in the following specific examples:
[0024] Embodiment 1:
[0025] An influenza antibody, comprising a light chain variable region, wherein the light chain variable region has an amino acid sequence shown in SEQ ID NO: 1.
[0026] Specifically, the structural modeling diagram of influenza antibodies is as follows Figure 1 As shown, the sequence of SEQ ID NO: 1 is SEQUENCELISTING.
[0027] Furthermore, the influenza antibody is of the type of immunoglobulin molecule, complementary determining region fragment, nanobody, single-chain antibody, double-chain antibody, three-chain antibody or four-chain antibody.
[0028] Embodiment 2:
[0029] A method for preparing influenza antibodies comprises the following steps:
[0030] Optimize the site selection, and screen the side chain amino acids located in the binding epitope through antibody and HA docking analysis.
[0031] The amino acid sequence shown in SEQ ID NO: 1 in the influenza antibody of Example 1 was inserted into the eukaryotic expression vector PVAX1, and transfected into the supernatant of Expi-CHO cells for expression;
[0032] When the cell survival rate reaches 70%, the supernatant is taken out for purification by Protein A affinity chromatography to obtain the antibody.
[0033] Understandably, if Figure 2 As shown, the purity of the obtained antibody was over 90%, and it was named 3W40I.
[0034] (1) Binding activity detection:
[0035] Indirect ELISA was used to detect the binding activity of the optimized antibody to H1, H3 and H5 HA proteins. The results are as follows: Figure 3 As shown, the average binding activity results showed that 3W40I had an 8-fold increase in binding activity compared to 3WT.
[0036] (2) Virus neutralization activity detection:
[0037] Mix 50 μL of 100×TCID50 virus with 50 μL of gradient diluted antibody and incubate at 37°C for 1 hour. Add the above virus-antibody mixture to MDCK monolayer cells and incubate at 37°C for 18-20 hours. After fixation with 80% cold acetone, detect the virus content in the cells by ELISA. The results are as follows: Figure 4 As shown, 3W40I has stronger virus neutralizing activity than 3W40I.
[0038] (3) Analysis of the antiviral mechanism of optimized antibodies:
[0039] Detection of antibody inhibition of virus entry: 50 μl of 0×TCID50 virus was incubated with an equal volume of 10 μg / mL antibody at 37°C for 1 hour, added to MDCK confluent monolayer cells and incubated for 2 hours, and then placed in 2% DMEM maintenance medium at 37°C for another 16-18 hours. The supernatant was removed, and the cells were fixed with 4% paraformaldehyde for subsequent immunofluorescence detection, such as Figure 5 As shown in middle A, 3W40I significantly inhibited viral invasion compared with 3WT.
[0040] Detection of antibody inhibition of virus spread: Add 0.7×TCID50 of virus, infect at 37℃ for 4h, add different concentrations of antibody and control antibody dilution (2μg / mL, 0.2μg / mL and 0.02μg / mL), and culture in a 37℃ incubator for 18h. Collect cell supernatant and cells by centrifugation, lyse cells with lysis buffer, and analyze the virus content contained in supernatant and cell lysate by Western blot, such as Figure 5 As shown in C, 3W40I has a stronger ability to inhibit the spread of the virus.
[0041] (4) Analysis of the in vivo preventive effect of optimized antibodies:
[0042] 3mg / kg and 1mg / kg of antibody and an equal volume of PBS were administered intravenously. 24h later, the mice were challenged nasally with influenza virus (A / HongKong / 01 / 1968 (H3N2), A / NY / 01 / 2009 (H1N1)) at a dose of 25 times EID50. The weight of the mice was monitored continuously for 14 days from the first day of immunization. On the 8th day after immunization, the lung tissue was taken for lung virus load and H&E staining. The results showed that 3W40I had a stronger antiviral effect than 3WT.
[0043] Embodiment 3:
[0044] An influenza antibody preparation, comprising the influenza antibody of Example 1.
[0045] Embodiment 4:
[0046] A pharmaceutical composition comprising the influenza antibody described in Example 1 and a carrier thereof.
[0047] The above is only a preferred specific embodiment of the present invention, but the protection scope of the present invention is not limited thereto. Any changes or substitutions that can be easily thought of by a person skilled in the art within the technical scope disclosed by the present invention should be included in the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
[0048]
[0049]
[0050]
Claims
1. An influenza antibody, It is characterized in that The influenza antibody comprises a light chain variable region having an amino acid sequence shown in SEQ ID NO:
1.
2. The influenza antibody according to claim 1, It is characterized in that The influenza antibody is of the type of immunoglobulin molecule, complementary determining region fragment, nanobody, single-chain antibody, double-chain antibody, three-chain antibody or four-chain antibody.
3. A method for preparing influenza antibodies, It is characterized in that The following steps are involved: Inserting the amino acid sequence shown in SEQ ID NO: 1 in the influenza antibody of claim 1 into the eukaryotic expression vector PVAX1, and transfecting it into the supernatant of Expi-CHO cells for expression; When the cell survival rate reaches 70%, the supernatant is taken out for purification by Protein A affinity chromatography to obtain the antibody.
4. The method for preparing influenza antibodies according to claim 3, It is characterized in that Also includes: The screening of optimized sites was carried out by analyzing the docking of antibodies and HA and screening the side chain amino acids located in the binding epitope.
5. An influenza antibody preparation, It is characterized in that The influenza antibody preparation comprises the influenza antibody according to claim 1.
6. A pharmaceutical composition, It is characterized in that The invention comprises the influenza antibody according to claim 1 and a carrier thereof.
Citation Information
Patent Citations
Broad-Spectrum Monoclonal Antibody Recognizing HA1 Domain of Hemagglutinin of Influenza Virus
US20160145320A1
Neutralising antibody for h7 type influenza a virus, and use thereof
WO2015131836A1
Broadly neutralizing fully human antibodies directed against influenza virus
WO2020143799A1
Cited By
Influenza antibody variant, application and transformation method
CN120463804A
Influenza antibody variant, use and modification method
CN120463804B
